Stock JAGX JAGUAR HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Real-time Estimate Cboe BZX
Other stock markets
 09:42:11 2024-05-20 am EDT 		5-day change 1st Jan Change
0.149 USD -42.36% Intraday chart for Jaguar Health, Inc. -11.50% +70.74%
May. 17 Jaguar Health Plans 1-for-60 Reverse Split Next Week MT
May. 14 Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jaguar Health Plans 1-for-60 Reverse Split Next Week
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration
Venture Life renews revolving credit facility with Santander and HSBC
Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes
Top Premarket Gainers
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Top Premarket Gainers
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Jaguar Health's Napo Pharmaceuticals Awaits Data on Phase 3 Trial of Crofelemer; Shares Fall
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAGX Stock
  4. News Jaguar Health, Inc.
  5. Other languages
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW